Osteoarthritis research shows progress in pain relief and cartilage repair

New research highlights significant advancements in treating knee osteoarthritis, moving from symptom management toward potential tissue repair and non-opioid pain relief.

A phase 2 randomized clinical trial published in The Lancet indicates that LEVI-04, an investigational p75 neurotrophin receptor fusion protein, significantly reduced pain and improved function in patients. The therapy targets neurotrophin-3 (NT-3) to inhibit pain and tissue degeneration. Results showed a dose-dependent reduction in WOMAC pain scores across all active treatment groups, with the therapy being well tolerated in participants from Denmark, Hong Kong, Poland, Moldova, and the Czech Republic.

In parallel, preclinical studies highlighted by Stanford Medicine are exploring methods to regenerate damaged cartilage and bone. Researchers identified the protein 15-PGDH as a key driver of joint degeneration; inhibiting this protein has shown promise in restoring cartilage thickness and flexibility in laboratory models. These experimental approaches aim to address the underlying biological causes of osteoarthritis rather than merely masking pain through traditional analgesics.